SI1631251T1 - Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra - Google Patents

Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra

Info

Publication number
SI1631251T1
SI1631251T1 SI200431744T SI200431744T SI1631251T1 SI 1631251 T1 SI1631251 T1 SI 1631251T1 SI 200431744 T SI200431744 T SI 200431744T SI 200431744 T SI200431744 T SI 200431744T SI 1631251 T1 SI1631251 T1 SI 1631251T1
Authority
SI
Slovenia
Prior art keywords
delayed release
release tablet
coating
core geometry
defined core
Prior art date
Application number
SI200431744T
Other languages
English (en)
Inventor
Guy Vergnault
Pascal Grenier
Christophe Dragan
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33306519&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1631251(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of SI1631251T1 publication Critical patent/SI1631251T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200431744T 2003-04-24 2004-04-23 Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra SI1631251T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0309342 2003-04-24
PCT/IB2004/001693 WO2004093843A1 (en) 2003-04-24 2004-04-23 Delayed release tablet with defined core geometry
EP04729170A EP1631251B1 (en) 2003-04-24 2004-04-23 Delayed release tablet with defined core geometry

Publications (1)

Publication Number Publication Date
SI1631251T1 true SI1631251T1 (sl) 2011-10-28

Family

ID=33306519

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431744T SI1631251T1 (sl) 2003-04-24 2004-04-23 Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra

Country Status (20)

Country Link
US (6) US8168218B2 (sl)
EP (1) EP1631251B1 (sl)
JP (1) JP4790597B2 (sl)
KR (1) KR101192722B1 (sl)
CN (2) CN1777412A (sl)
AT (1) ATE512659T1 (sl)
AU (1) AU2004231362B2 (sl)
BR (1) BRPI0409652A (sl)
CA (1) CA2523158C (sl)
CY (1) CY1111835T1 (sl)
DK (1) DK1631251T3 (sl)
ES (1) ES2368066T3 (sl)
IL (1) IL171494A (sl)
MX (1) MXPA05011446A (sl)
PL (1) PL1631251T3 (sl)
PT (1) PT1631251E (sl)
RU (1) RU2391093C2 (sl)
SI (1) SI1631251T1 (sl)
WO (1) WO2004093843A1 (sl)
ZA (1) ZA200509477B (sl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
ATE445393T1 (de) * 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
AU2004231362B2 (en) 2003-04-24 2009-11-12 Jagotec Ag Delayed release tablet with defined core geometry
WO2005123039A1 (en) 2004-06-12 2005-12-29 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
JP5161075B2 (ja) * 2005-06-03 2013-03-13 エガレット エイ／エス 分散媒体の第１フラクションとマトリックスの第２フラクションを有し、第２フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物
UA91376C2 (ru) * 2005-08-24 2010-07-26 Рубикон Рисеч Пвт Лтд. Рецептура с контролируемым высвобождением
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
MX2009001248A (es) * 2006-08-03 2009-02-11 Nitec Pharma Ag Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide.
EP2121107B1 (en) * 2006-12-18 2012-10-31 Eatlittle Inc. Device for delivery of a substance
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US10363221B2 (en) * 2007-10-17 2019-07-30 I-Property Holding Corp. Manufacturing solid pharmaceutical dosage forms with visible micro- and nanostructured surfaces and micro- and nanostructured pharmaceutical dosage form
US20090214599A1 (en) * 2008-02-21 2009-08-27 Agi Therapeutics Plc Proton pump inhibitor formulations, and methods of preparing and using such formulations
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
EP2393487B1 (en) 2009-02-06 2016-11-02 Egalet Ltd. Pharmaceutical compositions resistant to abuse
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
EP2554168B1 (en) 2010-03-29 2018-01-24 Astellas Pharma Inc. Controlled release pharmaceutical composition
WO2012080833A2 (en) 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
RS56344B1 (sr) 2010-12-22 2017-12-29 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
WO2013030726A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Programmed drug delivery
RU2471479C1 (ru) * 2012-02-13 2013-01-10 Общество с ограниченной ответственностью "Агентство редких лекарств и технологий" Фармацевтическая композиция в форме таблетки для перорального введения, содержащая в качестве активного компонента дексаметазон, и способ ее получения
US20130243861A1 (en) * 2012-03-16 2013-09-19 Cadila Healthcare Limited Press-coated tablets of prednisone
JP5818219B2 (ja) * 2012-05-14 2015-11-18 塩野義製薬株式会社 ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
PL2854769T3 (pl) * 2012-07-05 2023-08-07 Taiwan Liposome Company, Ltd. Sposoby leczenia zapalenia stawów
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
WO2016114726A1 (en) * 2015-01-12 2016-07-21 Ilko Ilaç Sanayi Ve Ticaret Anonim Şirketi Time-controlled prednisone delayed release tablet
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3047325A1 (en) * 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Solid pharmaceutical formulations of asimadoline
CN114588124B (zh) * 2020-12-07 2023-10-20 江苏恒瑞医药股份有限公司 一种延迟释放的药物组合物
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB874586A (en) 1957-10-28 1961-08-10 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
DE59005781D1 (de) 1990-07-02 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur herstellung geformter, verpresster dosiseinheiten mit retardierter freisetzung und entsprechende dosiseinheit.
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
WO1992011845A1 (en) 1991-01-03 1992-07-23 Glaxo Canada Inc. Method for production of solid pharmaceutical preparation
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
AU3949093A (en) 1992-03-31 1993-11-08 Benzon Pharma A/S A pharmaceutical formulation
JPH07507564A (ja) 1992-09-30 1995-08-24 ファイザー・インク． コア及び厚さが一定でないコーティングを含有する物品
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5567969A (en) * 1995-04-20 1996-10-22 Hall; John H. Compound modulated integrated transistor structure with reduced bipolar switch back effect
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
HUP0002296A3 (en) 1997-07-01 2001-11-28 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
KR20010031034A (ko) 1997-10-09 2001-04-16 페리오 프로덕츠 리미티드 전체 방출을 지연시키는 위장의 약물 송달 시스템
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
EP1067910B1 (en) 1998-04-03 2004-05-26 Egalet A/S Controlled release composition
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
GB9905898D0 (en) * 1999-03-15 1999-05-05 Darwin Discovery Ltd Controlled-dose formulation
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
JP2001010950A (ja) 1999-06-29 2001-01-16 Taiyo Yakuhin Kogyo Kk 安定で良好な薬物放出を有する医薬組成物
EP1074249A1 (en) 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10012555A1 (de) 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001247887A1 (en) 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
HUP0501071A3 (en) * 2001-03-13 2007-06-28 Penwest Pharmaceutical Co Chronotherapeutic dosage forms
NZ532568A (en) 2001-09-28 2005-07-29 Mcneil Ppc Inc Modified release dosage forms
KR20040091135A (ko) 2002-03-14 2004-10-27 다이이찌 산토리 파마 가부시키가이샤 염산 필지카이니드 함유 정제(건식)
EP1545472B1 (en) 2002-09-28 2010-12-08 McNeil-PPC, Inc. Modified release dosage forms with two cores and an opening
ATE445393T1 (de) 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
AU2004231362B2 (en) * 2003-04-24 2009-11-12 Jagotec Ag Delayed release tablet with defined core geometry
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20050118267A1 (en) 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
DE102004043863A1 (de) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum

Also Published As

Publication number Publication date
US9884021B2 (en) 2018-02-06
ZA200509477B (en) 2006-09-27
KR101192722B1 (ko) 2012-10-18
PT1631251E (pt) 2011-09-19
KR20060015528A (ko) 2006-02-17
RU2005132451A (ru) 2006-06-10
PL1631251T3 (pl) 2011-12-30
CN1777412A (zh) 2006-05-24
CN102525993A (zh) 2012-07-04
AU2004231362A1 (en) 2004-11-04
CA2523158C (en) 2010-11-16
US9040085B2 (en) 2015-05-26
US20140328912A1 (en) 2014-11-06
CN102525993B (zh) 2017-04-12
RU2391093C2 (ru) 2010-06-10
US20070110807A1 (en) 2007-05-17
US20160256396A1 (en) 2016-09-08
AU2004231362B2 (en) 2009-11-12
DK1631251T3 (da) 2011-10-03
JP2006524229A (ja) 2006-10-26
BRPI0409652A (pt) 2006-04-25
IL171494A (en) 2011-04-28
ATE512659T1 (de) 2011-07-15
CA2523158A1 (en) 2004-11-04
EP1631251B1 (en) 2011-06-15
US8168218B2 (en) 2012-05-01
US20120177734A1 (en) 2012-07-12
MXPA05011446A (es) 2006-05-31
JP4790597B2 (ja) 2011-10-12
ES2368066T3 (es) 2011-11-14
US20120177739A1 (en) 2012-07-12
WO2004093843A1 (en) 2004-11-04
EP1631251A1 (en) 2006-03-08
US9186332B2 (en) 2015-11-17
CY1111835T1 (el) 2015-10-07
US8394407B2 (en) 2013-03-12
US20130122061A1 (en) 2013-05-16
US8309124B2 (en) 2012-11-13

Similar Documents

Publication Publication Date Title
ZA200509477B (en) Delayed release tablet with defined core geometry
CA2199249A1 (en) Laminated tablet with pointed core
AR024492A1 (es) Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico
AP1748A (en) Chronotherapeutic dosage forms.
PL2057984T3 (pl) Tabletki z hydromorfonem o przedłużonym uwalnianiu
NO20032363L (no) Doseringsanordning for modifisert frigivelse
ATE268593T1 (de) Bupropionhydrochlorid enthaltende tabletten mit gesteuerter wirkstoffabgabe
NO20053245L (no) Tabletter med modifisert frigjoring av bupropionhydroklorid.
CA2409292A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
WO2005048923A3 (en) Extended release venlafaxine formulation
ATE322819T1 (de) Biozides puder mit verzögerter freisetzung
HK1039054A1 (en) Controlled release tablet comprising a hypoglycemic drug and an antihyperglycemic drug.
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
PT1405621E (pt) Processo de prepara??o de comprimidos
WO2005027843A3 (en) Chronotherapeutic dosage forms
CA2543353A1 (en) Oral drug delivery system
AUPR098400A0 (en) Production of radionuclide coated microspheres and seeds
TW200517146A (en) Novel composition
TW200714375A (en) Coating of surfaces and particles useful therefor
WO2005079763A3 (en) Compression-coated tablets and manufacture thereof
MY139719A (en) Oral dosage form for controlled drug release
ATE249208T1 (de) Geschmacksmaskierte kautablette mit sofortiger wirkstofffreisetzung sowie herstellungsverfahren
WO2007072060A3 (en) Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
WO2011093612A3 (en) Oral complex composition comprising pseudoephedrine and levocetirizine
ATE328587T1 (de) Feste pharmazeutische zusammensetzung enthaltend tilidinhydrochlorid